The San Diego Biotech Survival Index: Local Firms Make Strong Rebound In First Half of 2009

Luke Timmerman9/23/09Leave a CommentFollow @ldtimmerman

Share

Order a Reprint E-mail this Story

• Tweet

(Page 2 of 4)

Ardea Biosciences (NASDAQ: RDEA)
Cash on hand: $70.1 million
Previous Xconomy coverage:
“Ardea, Developer of Gout Drug, Sees Early Signs of Effectiveness”
“Ardea Biosciences, In Moment of Serendipity, Discovers HIV Drug That May Work for Gout”

Arena Pharmaceuticals (NASDAQ: ARNA)
Cash on hand: $39.6 million
Previous Xconomy coverage:
“Arena Eagerly Awaits Answer to $1 Billion Question: Does It Have a Big-Time Obesity Drug?”
“Arena Obesity Drug Helps Patients Shed a Few Pounds, Lower Risk of Heart Disease”
“Arena Drug Passes Second Trial, Aims to Sell Safe Option for Millions of People”

Cadence Pharmaceuticals (NASDAQ: CADX)
Cash on hand: $105.4 million
Previous Xconomy coverage:
“Cadence Turns Attention to Marketplace as IV Pain Reliever Reaches Goals in Clinical Trials”
“Cadence, Aiming to Reduce Narcotics Use in Hospitals, Gears Up to Market IV Pain Reliever”

Cypress Bioscience (NASDAQ: CYPB)
Cash on hand: $151.3 million
Previous Xconomy coverage:
“Cypress Bioscience, Developer of Fibromyalgia Drug, Eagerly Awaits FDA Deadline“
“Cypress Bioscience Shares Soar on News of FDA Approval”

Cytori Therapeutics (NASDAQ: CYTX)
Cash on hand: $13.9 million
Previous Xconomy coverage:
“San Diego’s Cytori Gains Cash, Loses a Patent“
“Cytori Expands GE Partnership, Raises More Cash“
“Cytori Raises $10 Million”

To purchase a much expanded version of this report, in PDF format, click the “Add to Cart” button. For $95,* you’ll get an assessment of each company’s financial position at the end of June compared to six months earlier, the projected length of time it can survive on its existing cash reserves, and an analysis of the strategic moves it has made to stay afloat in the current environment. Click here to see a sample entry. *Price is subject to change without notice.

Gen-Probe (NASDAQ: GPRO)
Cash on hand: $464.2 million
Previous Xconomy coverage:
“Gen-Probe Spins Off New Company, Roka Bioscience, for Industrial Testing“
“Gen-Probe Amends Deal to Get Promising Test for Prostate Cancer”

Genoptix Medical (NASDAQ: GXDX)
Cash on hand: $126.7 million
Previous Xconomy coverage:
“Riding a Cancer Diagnostics Wave, Genoptix Sees Boom Continuing in 2009”

Halozyme Therapeutics (NASDAQ: HALO)
Cash on hand: $89.2 million
Previous Xconomy coverage:
“Halozyme Set for Secondary Offering”
… Next Page »

Luke Timmerman is the National Biotech Editor of Xconomy, and the Editor of Xconomy Seattle. E-mail him at ltimmerman@xconomy.com or follow him on Twitter at twitter.com/ldtimmerman.